CITIC Securities

Jiangxi Bank Co has raised HK$7.48bn ($953m) from its Hong Kong IPO, pricing the shares towards the top of guidance thanks to a big group of flexible investors.

Thunder Bridge Acquisition began trading on the Nasdaq this week after sealing a $230m IPO. It is the first special purpose acquisition vehicle (Spac) to focus purely on China’s financial technology sector.

Qeeka Home, an online interior design and construction platform, kicked off bookbuilding this week for a HK$2.18bn ($277.6m) IPO.

Chinese technology giant Xiaomi Corp kicked off bookbuilding for its up to HK$48bn ($6.1bn) Hong Kong IPO on Thursday, set to be the largest globally in nearly two years, after a series of twists and turns that put it firmly on the market’s radar. Jonathan Breen reports.

Smartphone and devices manufacturer Xiaomi Corp has put the China Depository Receipt (CDR) portion of its $10bn IPO on hold, opting to list in Hong Kong first.

Xiaomi Corp has said that about half of its expected $10bn dual listing in Hong Kong and China will come from the offering of China Depositary Receipts to Mainland investors.

Wise Talent Information Technology, owner of recruitment website Liepin.com, has opened books for its up to HK$3.1bn ($398.1m) Hong Kong IPO.

Jiangxi Bank Co has kicked off a week-long roadshow for its up to HK$7.8bn ($992.9m) Hong Kong IPO, set to be the second largest listing in the city so far this year.

Puxin and VCredit Holdings, both of which launched IPOs earlier this week, were covered on their first day of bookbuilding.

Xiaomi Corp had its listing hearing with the Hong Kong Stock Exchange on Thursday, paving the way for investor education to begin on Monday if the IPO is approved.

General Motors’ joint venture sealed a Rmb10.4bn ($1.62bn) deal in the Chinese securitization market on June 6, marking its biggest outing so far. Bankers on the deal said the auto company wanted to bag the cash before onshore rates come under pressure in the second half of the year.

Hua Medicine has filed for an IPO in Hong Kong under sponsors CLSA and Goldman Sachs, as the promised pipeline of biotechnology issuers begins to materialise following the city’s new listing rules.